GenSight Biologics announced that the Company’s country leads for three key European markets are in place. Laurence Rodriguez, Robert Schupp and Neil Dugdale have joined the Company as the country leads for France, Germany and the United Kingdom, respectively, marking an important milestone in local preparations to commercialize LUMEVOQ® in H1 2022. Laurence Rodriguez joins GenSight with over 30 years’ experience in the life sciences industry, including 13 years in the rare diseases business at Sanofi Genzyme, where she held a range of commercial roles such as Marketing Manager, Marketing and Sales Manager and Business Unit Director. As Head of the Rare Diseases & Rare Blood Disorders unit at Sanofi Genzyme, she oversaw the successful launch of a number of rare disease products developed or acquired by the company. Robert Schupp brings more than 30 years of commercial life sciences experience to GenSight, including success building the commercial organization and rare disease franchise at Celgene in Germany and establishing the ultra-rare disease franchise of Santhera in Germany, Austria and Switzerland. His five years in the General Manager role at Santhera enabled him to build a strong network among LHON stakeholders, marked by successfully achieving reimbursement for Raxone® in Germany. Neil Dugdale joins GenSight after more than 25 years in a range of commercial leadership roles, most recently as the Vice President of the Northern Europe sub-region and General Manager of the UK and Ireland at Sobi (Swedish Orphan Biovitrum AB). He led the commercial launch of Sobi’s treatments for hemophilia in the UK and Ireland and the launch planning for primary hemophagocytic lymphohistiocytosis (HLH) and thrombocytopenia.